Clinical trials: STI
Hiv
HIV-Related Stigma Intervention for Malaysian Clinicians
Key populations at risk of HIV (including men who have sex with men, people who inject drugs, transgender women, and female sex workers) are more likely to be infected with HIV but less likely than members of the general…
- Trial name
- NCT05597787
- Testing
- HIV Connect, Project ECHO for HIV Prevention, Project ECHO for HIV Prevention and Stigma Reduction
- Where
- Malaysia
- Volunteers
- 78 people
- Sponsor
- University of Delaware
HIV Infections, Sexually Transmitted Diseases
Reducing HIV Risk Among Adolescents: Evaluating HEART for Teens
This study evaluates an educational web-based intervention designed to increase adolescent boys' and girls' motivation and skills to engage in safer sexual behavior (HEART: Health Education and Relationship Training).
- Trial name
- NCT03453515
- Testing
- HEART, Growing Minds
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- North Carolina State University
Cervical Cancer
Human Papillomavirus Infection and Virus Genotyping in Uterine Cervix Cancer in Venezuela
1. Hypothesis: If high risk genotypes of human papillomavirus (HPV) is the cause of cervical cancer worldwide, the genotypes associated with cervical cancer in Venezuela would be the same types found in other countries. 2.
- Trial name
- HPI (NCT00937547)
- Where
- 2 sites in Venezuela
- Volunteers
- 329 people
- Sponsor
- Instituto Oncologico Luis Razetti
Hiv, HIV/AIDS
AllyQuest: Engaging HIV+ YMSM in Care Through Social Networking and Gamification
AllyQuest is a novel, high impact secondary prevention intervention delivered via mobile phones to improve linkage and engagement in care among newly diagnosed HIV+ young men who have sex with men (YMSM).
- Trial name
- AQ (NCT03090958)
- Testing
- AllyQuest
- Volunteers
- 20 people
- Sponsor
- University of North Carolina, Chapel Hill
Hiv
Prospective Cohort Study of Adolescents Living With HIV and Their Caregivers Attending a Psychosocial Programme in Botswana
Adolescents/young adults with perinatally acquired HIV (PAH) face a number of antiretroviral (ART) adherence and well-being challenges.
- Trial name
- NCT03571555
- Testing
- Sentebale Psychosocial Programme
- Where
- Botswana
- Volunteers
- 516 people
- Sponsor
- Royal Holloway University
AIDS
Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine
A pilot 24-week open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of dual therapy with Raltegravir/Lamivudine combination when replacing standard combination therapy in HIV-infected…
- Trial name
- RALAM (NCT02284035)
- Testing
- Raltegravir/3TC, EFV/TDF/FTC, ATV/r + TDF/FTC or DRV/r + TDF/FTC
- Where
- Spain
- Volunteers
- 75 people
- Sponsor
- Juan A. Arnaiz
HIV Infections
Implementation a Data-to-Care Strategy to Improve HIV Continuum Outcomes for Out of Care People Living With HIV (PLWH) in Ukraine
The goal of this clinical trial is to study the preliminary effectiveness of a data to care intervention versus standard of care for people living with HIV in Ukraine.
- Trial name
- NCT05821413
- Testing
- Data to care, Standard of Care
- Where
- Ukraine
- Volunteers
- 160 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Infections
Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine
The purpose of this study is to evaluate the safety and immune response to an HIV clade C vaccine and to an MF59- or alum-adjuvanted clade C Env protein in healthy, HIV-uninfected adults.
- Trial name
- HVTN107 (NCT03284710)
- Testing
- ALVAC-HIV (vCP2438), Bivalent Subtype C gp120/MF59, Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension
- Where
- 6 sites in Mozambique, South Africa and 1 more
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Tobacco Use Cessation
Tobacco Cessation Tailored to Patients Living With HIV (PLWH) in Brazil
The overall goal of this feasibility study is to make adaptations to these evidence-based approaches in collaboration with PLWH and health care providers working with this population, and develop, implement, and evaluate the…
- Trial name
- NCT05560243
- Testing
- Tobacco cessation
- Where
- Brazil
- Volunteers
- 56 people
- Sponsor
- University of Alabama at Birmingham
Infection, Human Immunodeficiency Virus I
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50 mg plus Abacavir/Lamivudine once daily versus Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate (ATRIPLA® a trade mark of…
- Trial name
- NCT01263015
- Testing
- Dolutegravir, Atripla, Abacavir/Lamivudine
- Where
- 145 sites in United States, Australia and 10 more
- Volunteers
- 844 people
- Sponsor
- ViiV Healthcare
Human Papillomavirus (HPV) Infection
GARDASIL Reexamination Study (V501-059)
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of Gardasil through collecting…
- Trial name
- NCT01062074
- Volunteers
- 3,605 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Immunization Status, Well Child Care Visit
Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients
The investigators will design and implement a randomized clinical trial to test, on a community-wide level, the effectiveness of managed care based tracking/reminder/recall on improving vaccination coverage among adolescents.
- Trial name
- NCT01057888
- Testing
- Autodialer, Letters
- Volunteers
- 10,599 people
- Sponsor
- University of California, Los Angeles
HIV Infection, Infection, Human Immunodeficiency Virus
A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects
This is a 24-week study to evaluate the efficacy and safety of a once-daily ritonavir-boosted fosamprenavir regimen (1400mg/100mg QD) to a 200mg ritonavir-boosted fosamprenavir regimen administered either twice-daily or…
- Trial name
- NCT00363142
- Testing
- Half-boosted Fosamprenavir, Full Boosted Fosamprenavir
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 211 people
- Sponsor
- GlaxoSmithKline
HIV Disease
Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease
Our primary objective is to further characterize the mechanism by which alpha-1PI regulates CD4 counts. HIV-1 infected patients will be initiated on PROLASTIN®-C (Alpha-1 Proteinase Inhibitor [Human], Grifols Biotherapeutics…
- Trial name
- NCT01731691
- Testing
- α1 Proteinase Inhibitor
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Institute for Human Genetics and Biochemistry
HIV Infections, Metabolic Syndrome X
Lifestyle Modification and Metformin Use in the Treatment of HIV
A healthy diet and exercise have improved the health of people without human immunodeficiency virus (HIV) who have Metabolic Syndrome.
- Trial name
- NCT00399360
- Testing
- Metformin, Lifestyle Modification
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Pregnancy, Sexually Transmitted Infections
Contraceptive Awareness and Reproductive Education
The long-term objectives of this research are to develop effective treatments to reduce unplanned pregnancy and Sexually Transmitted Infections (STIs) for a highly under-served at-risk youth population.
- Trial name
- NCT01627574
- Testing
- Motivational Intervention, Didactic Educational Intervention
- Where
- 5 sites in United States
- Volunteers
- 272 people, healthy volunteers welcome
- Sponsor
- University of Rhode Island
Infection, Human Immunodeficiency Virus
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
Integrase is an enzyme produced by HIV so that the virus can multiply in the human body. GSK1349572 is a new drug in the integrase inhibitor class that prevents the enzyme from working properly and therefore prevents the virus…
- Trial name
- NCT00950859
- Testing
- GSK1349572 (Cohort I), GSK1349572 (Cohort II)
- Where
- 26 sites in United States, Canada and 3 more
- Volunteers
- 51 people
- Sponsor
- ViiV Healthcare
HIV Infections
Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
This study will evaluate the safety and efficacy of the long-acting injectable agent cabotegravir (CAB LA) compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) in…
- Trial name
- NCT03164564
- Testing
- Oral CAB, Oral TDF/FTC, CAB LA
- Where
- 20 sites in Botswana, Eswatini and 5 more
- Volunteers
- 3,224 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672)
Vicriviroc (vye-kri-VYE-rock) is an investigational drug that belongs to a new class of drugs, called C-C chemokine receptor type 5 (CCR5) receptor blockers.
- Trial name
- VICTOR-E1 (NCT00243230)
- Testing
- Vicriviroc 30 mg, Vicriviroc 20 mg, Background ART Regimen
- Volunteers
- 116 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1 Infections, HIV Infections
Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples
Randomized, blinded, placebo-controlled trial to demonstrate if pre-exposure prophylaxis decreases HIV-1 acquisition among HIV-1 uninfected individuals within HIV-1 discordant couples.
- Trial name
- Partners PrEP (NCT00557245)
- Testing
- Tenofovir Disoproxil Fumarate (TDF), Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)
- Where
- 9 sites in Kenya, Uganda
- Volunteers
- 4,758 people, healthy volunteers welcome
- Sponsor
- University of Washington